Company / Current Assets
Enliven Therapeutics, Inc. Current Assets History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$318.1M
FY2024
5-year range
$77.8M / $318.1M
FY2020-FY2024
Trend
+19.5%
vs FY2023
Sector context
#158 of 213
Health Care
What the data says
At $318M, Enliven Therapeutics, Inc.'s current assets ranks #158 of 213 in the Health Care sector. Improved from $78M to $318M over the past 2 years.
Based on SEC 10-K filings.
$318M in FY2024 with a 5-year CAGR of +59.7%.
Improved from $78M to $318M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +50.8%
- 5-Year CAGR
- +59.7%
- 10-Year CAGR
- -
Sector benchmark
#158 of 213 in Health CareTop 74% of 213This company $318.1M Sector average $2.5B
▼
-87.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +59.7%, indicating consistent growth.
- In FY2024, current assets increased 19.5% year-over-year.
- Ranks #158 out of 213 companies in the Health Care sector.
- Lowest current assets in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $318.1M | +19.5% |
| FY2023 | $266.2M | +242.3% |
| FY2022 | $77.8M | -16.1% |
| FY2021 | $92.7M | +2.5% |
| FY2020 | $90.4M | +195.2% |
| FY2019 | $30.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026